CCA
BLPH

Catalyst Capital Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Catalyst Capital Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,667
Closed -$912K – 647
2015
Q2 		$912K Hold
7,667
– – 0.11% 164
2015
Q1 		$1.06M Buy
+7,667
New +$1.19M 0.12% 142

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Catalyst Capital Advisors's BLPH Position: Q3 2015 in Review

Catalyst Capital Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2015, closing a stake of 7,667 shares — an estimated $912K sold.

Catalyst Capital Advisors first reported a position in BLPH in Q1 2015 and held it in 2 quarters. The position peaked at $1.06M in Q1 2015. 15 funds tracked by Wall St. Rank hold BLPH as of Q3 2015.

  • Catalyst Capital Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Catalyst Capital Advisors sold 7,667 Bellerophon Therapeutics, Inc. shares in Q3 2015, an estimated $912K.
  • Catalyst Capital Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
  • Catalyst Capital Advisors's Bellerophon Therapeutics, Inc. position peaked at $1.06M in Q1 2015.
  • 15 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2015.

Based on Catalyst Capital Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.